R. Fisher

发表

Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways

L. Staudt, R. Davis, A. Rosenwald, 2008, Proceedings of the National Academy of Sciences.

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.

L. Staudt, A. Rosenwald, J. Powell, 2002, The New England journal of medicine.

Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma

L. Staudt, A. Rosenwald, Xin Yu, 2003, The Journal of experimental medicine.

Revised response criteria for malignant lymphoma.

Sigrid Stroobants, Bruce D Cheson, Lena Specht, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.

Bruce D Cheson, Lawrence H Schwartz, Emanuele Zucca, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells.

L. Staudt, A. Rosenwald, J. Powell, 2004, The New England journal of medicine.

Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction.

L. Staudt, A. Rosenwald, J. Powell, 2005, Blood.

The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma.

L. Staudt, A. Rosenwald, J. Powell, 2003, Cancer cell.

Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02.

R. Fisher, L. Peters, R. Hicks, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial.

R. Fisher, S. Fox, B. O'Sullivan, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group.

R. Fisher, J. Bourhis, B. O'Sullivan, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Stromal gene signatures in large-B-cell lymphomas.

L. Staudt, W. C. Chan, A. Rosenwald, 2008, The New England journal of medicine.

Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics

L. Staudt, A. Rosenwald, J. Powell, 2012, Nature.

A predictive model for aggressive non-Hodgkin's lymphoma.

Emili Montserrat, Christian Gisselbrecht, Carlo Tondini, 1993, The New England journal of medicine.

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.

Randy D Gascoyne, R. Gascoyne, R. Fisher, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny.

J. Friedberg, R. Fisher, E. Milner, 2007, Clinical immunology.

Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02.

Brian O'Sullivan, Jacques Bernier, Richard Fisher, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

Jan Delabie, Wenming Xiao, Weihong Xu, 2010, Nature.

A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517

L. Rimsza, R. Fisher, S. Forman, 2012, Leukemia & lymphoma.

Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma

Jan Delabie, Randy D Gascoyne, Weihong Xu, 2008, Science.

Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival.

Adrian Wiestner, Hui Liu, Kazutaka Nakayama, 2007, Blood.

Optimizing First-Line Therapy for Follicular Lymphoma: Is It Time for Chemotherapy-Free Approaches?

R. Fisher, 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

Long-Term Follow-up of 153 Candidates for Definitive Radiation or Chemoradiation Therapy with Non-Small Cell Lung Cancer Who Were Staged by PET: Implications for Design of Future Randomized Trials

R. Fisher, J. Matthews, R. Hicks, 2005 .

The impact of Hodgkin's disease on the immune system.

R. Fisher, J. Nawrocki, D. Slivnick, 1990, Seminars in oncology.

Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study.

J. Leonard, S. de Vos, R. Fisher, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

N2‐N3 neck nodal control without planned neck dissection for clinical/radiologic complete responders—Results of Trans Tasman Radiation Oncology Group Study 98.02

R. Fisher, L. Peters, D. Rischin, 2008, Head & neck.

High-dose aldesleukin in renal cell carcinoma: long-term survival update.

R. Fisher, S. Rosenberg, M. Sznol, 1997, The cancer journal from Scientific American.

Non-Hodgkin's lymphomas, version 4.2014.

J. Byrd, R. Advani, J. Vose, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

Effects of interleukin-2 immunotherapy on renal function.

R. Fisher, J. Hano, S. Creekmore, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Excess prevalence of Pneumocystis carinii pneumonia in patients treated for lymphoma with combination chemotherapy.

R. Fisher, D. Longo, P. Pizzo, 1986, Annals of internal medicine.

Autologous bone marrow transplantation using unfractionated cells cryopreserved in dimethylsulfoxide and hydroxyethyl starch without controlled-rate freezing.

R. Fisher, P. Stiff, A. Koester, 1987 .

CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+ T cells.

R. Fisher, H. Jäck, P. Simms, 1993, Journal of immunology.

The human T-cell leukemia-lymphoma virus in the southeastern United States.

E. Jaffe, R. Fisher, P. Bunn, 1983, JAMA.

The role of body mass index in survival outcome for lymphoma patients: US intergroup experience.

R. Gascoyne, L. Gordon, R. Fisher, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

The Bruton tyrosine kinase (BTK) inhibitor PCI‐32765 synergistically increases proteasome inhibitor activity in diffuse large‐B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib

J. Friedberg, R. Fisher, P. Dent, 2013, British journal of haematology.

Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T‐cell non‐Hodgkin lymphoma

R. Fisher, T. Miller, M. Leblanc, 2013, Cancer.

Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas

Derick R. Peterson, J. Friedberg, R. Fisher, 2016, Leukemia & lymphoma.

A randomized trial comparing local recurrence (LR) rates between short-course (SC) and long-course (LC) preoperative radiotherapy (RT) for clinical T3 rectal cancer: An intergroup trial (TROG, AGITG, CSSANZ, RACS).

Trog, R. Fisher, D. Goldstein, 2010 .

Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens.

A. LaCasce, J. Friedberg, R. Fisher, 2009, Clinical lymphoma & myeloma.

Reply to G. Keramida et al.

R. Fisher, L. Schwartz, B. Cheson, 2015, Journal of Clinical Oncology.

Oestrogen receptors in human malignant melanoma.

R. Fisher, M. Lippman, J. Neifeld, 1976, The Lancet.

Mantle-cell lymphoma: classification and therapeutic implications.

R. Fisher, Richard I. Fisher, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Relationship between Epidermal Growth Factor Receptor Status, p16INK4A, and Outcome in Head and Neck Squamous Cell Carcinoma

R. Fisher, S. Fox, B. Solomon, 2011, Cancer Epidemiology, Biomarkers & Prevention.

Correlation of p16 status, hypoxic imaging using [18F]‐misonidazole positron emission tomography and outcome in patients with loco‐regionally advanced head and neck cancer

R. Fisher, B. Solomon, L. Peters, 2014, Journal of medical imaging and radiation oncology.

Peritoneoscopy in the management of ovarian cancer.

R. Fisher, R. Makuch, R. Ozols, 1981, American journal of obstetrics and gynecology.

Iodine-131 tositumomab (Bexxar®): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin’s lymphoma

J. Friedberg, R. Fisher, 2004, Expert review of anticancer therapy.

Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma.

R. Fisher, R. Hicks, M. MacManus, 2002, The American journal of medicine.

Stage Is Not a Reliable Indicator of Tumor Volume in Non-small Cell Lung Cancer: A Preliminary Analysis of the Trans-Tasman Radiation Oncology Group 99-05 Database

R. Fisher, S. Vinod, D. Joseph, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Dose-volume histogram analysis as predictor of radiation pneumonitis in primary lung cancer patients treated with radiotherapy.

R. Fisher, D. Ball, M. M. Mac Manus, 2005, International Journal of Radiation Oncology, Biology, Physics.

Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: a Southwest Oncology Group Study.

R. Fisher, T. Grogan, T. Miller, 2001, Journal of Clinical Oncology.

IL-12 activates IFN-gamma production through the preferential activation of CD30+ T cells.

R. Fisher, H. Jäck, T. Ellis, 1995, Journal of immunology.

CD30 defines a subset of activated human T cells that produce IFN-gamma and IL-5 and exhibit enhanced B cell helper activity.

R. Fisher, H. Jäck, T. Ellis, 1994, Journal of immunology.

Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703).

Sonali M. Smith, J. Friedberg, L. Rimsza, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer.

R. Fisher, L. Peters, R. Fisher, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Late relapses following high-dose autologous stem cell transplantation (HD-ASCT) for Hodgkin's lymphoma (HL) in the ABVD therapeutic era.

J. Friedberg, R. Fisher, L. Constine, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase II study of the PD1-inhibitor pembrolizumab for the treatment of relapsed or refractory mature t-cell lymphoma.

Sonali M. Smith, R. Fisher, Y. Oki, 2018 .

R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre study.

Sonali M. Smith, J. Friedberg, R. Fisher, 2018, The Lancet. Haematology.

Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies.

G. Salles, J. Friedberg, L. Rimsza, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma.

Derick R. Peterson, J. Armitage, J. Vose, 2011, Blood.

lymphoma patients with relapsed/refractory indolent and mantle cell non-Hodgkin The combination of bendamustine, bortezomib, and rituximab for

J. Vose, R. Fisher, S. Grant, 2011 .

Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III Trial

R. Fisher, S. Fox, B. Solomon, 2010 .

Diversity of immunological phenotypes of lymphoblastic lymphoma.

R. Fisher, I. Magrath, J. Cossman, 1983, Cancer research.

The emerging concept of antigen-driven lymphomas: epidemiology and treatment implications

R. Fisher, S. Fisher, 2006, Current opinion in oncology.

Prognostic significance of HPV and p16 status in patients with oropharyngeal cancer treated on a large international phase III trial.

R. Fisher, S. Fox, B. O'Sullivan, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501.

R. Fisher, T. Grogan, T. Miller, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combination o f F ludarabine a nd M itoxantrone i n U ntreated Stages I II a nd I V L ow-Grade L ymphoma: S 9501

R. Fisher, T. Grogan, T. Miller, 2003 .

Treatment of grey zone lymphomas.

R. Fisher, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

CHOP therapy: has shorter-course therapy had an impact on lymphomas?

R. Fisher, E. Gaynor, 1998, Cancer investigation.

A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study.

R. Fisher, T. Grogan, T. Miller, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment of aggressive non‐hodgkin's lymphomas: Lessons from the past 10 years

R. Fisher, 1994 .

Bleomycin in non-Hodgkin's lymphoma.

R. Fisher, E. Gaynor, R. Bayer, 1992, Seminars in oncology.

Long-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas.

R. Fisher, D. Longo, T. Miller, 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

Renal involvement in diffuse aggressive lymphomas: results of treatment with combination chemotherapy.

R. Fisher, D. Longo, V. Devita, 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of diffuse large cell non-Hodgkin’s lymphomas

R. Fisher, D. Longo, V. Devita, 1985 .

Diffuse histiocytic lymphoma involving the gastrointestinal tract

R. Fisher, V. Devita, B. Chabner, 1978, Cancer.

Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy.

E. Jaffe, R. Fisher, P. Duffey, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Autologous bone marrow transplantation in adults with non‐Hodgkin's lymphoma: A southwest oncology group study

R. Fisher, C. Coltman, F. Appelbaum, 1994, Hematological oncology.

Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349).

R. Fisher, T. Grogan, T. Miller, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Simian virus 40 is present in most United States human mesotheliomas, but it is rarely present in non-Hodgkin's lymphoma.

R. Fisher, H. Pass, S. Fisher, 1999, Chest.

Central nervous system complications of non-Hodgkin's lymphoma. The potential role for prophylactic therapy.

E. Jaffe, R. Fisher, V. Devita, 1979, The American journal of medicine.

Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma.

R. Fisher, M. Atkins, G. Weiss, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials.

R. Fisher, J. Sosman, G. Weiss, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma.

R. Fisher, M. Atkins, J. Sosman, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 2 trial of CHOP chemotherapy followed by tositumomab / iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma : Southwest Oncology Group Protocol S 9911

R. Fisher, T. Miller, M. Leblanc, 2003 .

Randomized Phase III Trial Comparing ABVD + Radiotherapy and the Stanford V Regimen In Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the US Intergroup Trial E2496

R. Advani, R. Gascoyne, L. Gordon, 2010 .

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.

T M Grogan, T P Miller, R. Fisher, 1993, The New England journal of medicine.

Laboratory Study Cooperative Oncology Group and Southwest Oncology Group Cooperative Intermediate- and High-Grade Non-Hodgkin's Lymphomas: An Eastern BCL-2 Expression Correlates With Lower Proliferative Activity in the

L. Gordon, J. Winter, R. Fisher, 2013 .

Involved field radiation after autologous stem cell transplant for diffuse large B-cell lymphoma in the rituximab era.

J. Friedberg, R. Fisher, O. Hyrien, 2010, International journal of radiation oncology, biology, physics.

Treatment of diffuse large B-cell lymphomas.

R. Fisher, 2006, Seminars in hematology (Print).

Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma

J. Vose, M. Czuczman, R. Fisher, 2005, Leukemia & lymphoma.

Autologous stem-cell transplantation as a component of initial treatment for poor-risk patients with aggressive non-Hodgkin's lymphoma: resolved issues versus remaining opportunity.

R. Fisher, 2002, Journal of Clinical Oncology.

Autologous bone marrow transplantation for aggressive non-Hodgkin's lymphoma: lessons learned and challenges remaining.

R. Fisher, 2001, Journal of the National Cancer Institute.

Phase II Study of Rituximab in Combinat ion With CHOP Chemotherapy in Pat ients With Prev ious ly Untreated , Aggress ive Non-Hodgkin ’ s Lymphoma

J. Vose, M. Czuczman, R. Fisher, 2000 .

Clinical features and response to current treatment modalities in mantle cell lymphoma

R. Fisher, 1999 .

BCL-2 expression correlates with lower proliferative activity in the intermediate- and high-grade non-Hodgkin's lymphomas: an Eastern Cooperative Oncology Group and Southwest Oncology Group cooperative laboratory study.

L. Gordon, J. Winter, R. Fisher, 1998, Blood.

Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246.

R. Fisher, S. Balcerzak, O. Press, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cyclophosphamide, doxorubicin, vincristine, and prednisone versus intensive chemotherapy in non-Hodgkin’s lymphoma

R. Fisher, 1997, Cancer Chemotherapy and Pharmacology.

Chemotherapy of intermediate-grade non-Hodgkin's lymphoma: is "more" or "less" better?

R. Fisher, E. Gaynor, 1995, Oncology.

m-BACOD treatment for intermediate- and high-grade malignant lymphomas: a Southwest Oncology Group phase II trial.

R. Fisher, T. Miller, C. Coltman, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The human T-cell leukemia/lymphoma virus, lymphoma, lytic bone lesions, and hypercalcemia.

R. Fisher, M. Robert-Guroff, J. Cossman, 1983, Annals of internal medicine.

Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial.

R. Advani, R. Gascoyne, L. Gordon, 2013, Blood.

Reply to B. Bennani-Baiti et al, H.J.A. Adams et al, E. Laffon et al, and E.A. Hawkes et al.

F. Cavalli, T. Lister, R. Fisher, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Computed tomography of the liver and spleen with intravenous lipoid contrast material: review of 60 examinations.

R. Fisher, J. Doppman, B. Edwards, 1982, AJR. American journal of roentgenology.

Staging of non-Hodgkin's lymphoma.

R. Fisher, V. Devita, B. Chabner, 1980, Seminars in oncology.

Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity.

R. Fisher, M. Atkins, J. Sosman, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma.

J. Friedberg, J. Winter, L. Rimsza, 2013, The New England journal of medicine.

3008 ORAL Acute adverse events in a randomised trial of short course versus long course preoperative radiotherapy for T3 adenocarcinoma of rectum: a Trans-Tasman Radiation Oncology Group trial (TROG 01.04)

R. Fisher, D. Goldstein, D. Joseph, 2007 .

Diffuse Large B-Cell Lymphoma Subgroups Have Distinct Genetic Profiles that Influence Tumor Biology and Improve Gene Expression-Based Survival Prediction for the Lymphoma/Leukemia Molecular Profiling Project

Rita, Armitage, L. Staudt, 2005 .

Improving Goal Concordant Care Among 10 Leading Academic U.S. Cancer Hospitals: A Collaboration of the Alliance of Dedicated Cancer Centers

M. Caligiuri, R. Fisher, P. Hwu, 2021, The oncologist.

Persistent immunologic abnormalities in long-term survivors of advanced Hodgkin's disease.

R. Fisher, V. Devita, R. Young, 1980, Annals of internal medicine.

Hemostatic abnormalities in untreated cancer: incidence and correlation with thrombotic and hemorrhagic complications.

R. Fisher, R. Salgia, S. Fisher, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Title Prognostic significance of plasma osteopontin in patients with loco-regionally advanced head and neck squamous cell carcinoma treated on TROG 02 . 02 Phase III trial

R. Fisher, A. Giaccia, Q. Le, 2011 .

Prognostic Significance of Plasma Osteopontin in Patients with Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Treated on TROG 02.02 Phase III Trial

R. Fisher, A. Giaccia, Q. Le, 2011, Clinical Cancer Research.

Prognostic Signi fi cance of Plasma Osteopontin in Patients with Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Treated on TROG 02 . 02 Phase III Trial

R. Fisher, A. Giaccia, Q. Le, 2011 .

The role of myeloablation for lymphoma.

R. Fisher, J. Unger, P. Stiff, 2014, The New England journal of medicine.

Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab.

J. Friedberg, R. Fisher, R. J. Kelleher, 2009, Blood.

Adjuvant radiotherapy and regional lymph node field control in melanoma patients after lymphadenectomy: Results of an intergroup randomized trial (ANZMTG 01.02/TROG 02.01).

R. Fisher, K. Shannon, R. Scolyer, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inhibition of a specific DNA repair system and nitrosourea cytotoxicity in resistant human cancer cells.

R. Fisher, D. Barnes, B. Futscher, 1989, Cancer communications.

Increased sensitivity of T cells to regulation by normal suppressor cells persists in long-term survivors with Hodgkin's disease.

R. Fisher, C. Vanhaelen, 1982, The American journal of medicine.

Evidence for eosinophil activation in cancer patients receiving recombinant interleukin-4: effects of interleukin-4 alone and following interleukin-2 administration.

R. Fisher, J. Sosman, K. Offord, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects.

R. Fisher, M. Atkins, J. Sosman, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I clinical trial of recombinant interleukin-2 by periodic 24-hour intravenous infusions.

R. Fisher, J. Harris, M. Cahill, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Delphi-panel analysis of appropriateness of high-dose chemotherapy and blood cell or bone marrow autotransplants in diffuse large-cell lymphoma.

J. Armitage, P. Bierman, R. Fisher, 1998, Leukemia & lymphoma.

Non-Hodgkin's lymphomas, version 2.2014.

J. Byrd, R. Advani, J. Vose, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016.

J. Byrd, R. Advani, J. Vose, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Non-Hodgkin’s Lymphomas, Version 4.2014: Clinical Practice Guidelines in Oncology

J. Byrd, R. Advani, J. Vose, 2014 .

Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.

J. Byrd, R. Advani, J. Vose, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma.

R. Fisher, L. Rubinstein, M. Atkins, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of interleukin 2 on cardiac function in the isolated rat heart.

R. Fisher, P. Sobotka, J. McMannis, 1990, The Journal of clinical investigation.

Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines.

R. Fisher, M. Atkins, J. Doroshow, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunoblastic lymphadenopathy: Evolution into a malignant lymphoma with plasmacytoid features

E. Jaffe, R. Fisher, R. Braylan, 1976 .

Decreased Expression of Class II Major Histocompatibility Antigens on Monocytes From Patients With Hodgkin's Disease

R. Fisher, H. Nagai, J. Cossman, 1986, Journal of leukocyte biology.

Phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin's lymphoma (NHL): Southwest Oncology Group Study S0108

L. Rimsza, R. Fisher, T. Miller, 2005 .

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

J. Armitage, J. Vose, A. Hagenbeek, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Herpes zoster complicating bortezomib therapy of relapsed/refractory indolent B-cell and mantle cell lymphoma: an analysis of two phase II trials

R. Neuwirth, D. Esseltine, S. de Vos, 2013, Leukemia & lymphoma.

Phase II study of a TLR‐9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma

Derick R. Peterson, J. Friedberg, R. Fisher, 2009, British journal of haematology.

Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial.

R. Fisher, C. Coltman, J. Doroshow, 1988, Annals of internal medicine.

Aurora A Inhibitor (MLN8237) plus Vincristine plus Rituximab Is Synthetic Lethal and a Potential Curative Therapy in Aggressive B-cell Non-Hodgkin Lymphoma

R. Fisher, T. Miller, Ann M Manziello, 2012, Clinical Cancer Research.

Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial.

R. Fisher, K. Shannon, R. Scolyer, 2015, The Lancet. Oncology.

The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review.

J. Vose, M. Czuczman, R. Fisher, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Requirements for successful immunotherapy and chemoimmunotherapy of a murine model of ovarian cancer.

R. Fisher, C. Vanhaelen, 1981, Cancer research.

1-beta-D-arabinofuranosylcytosine and hydroxyurea production of cytotoxic synergy with cis-diamminedichloroplatinum(II) and modification of platinum-induced DNA interstrand cross-linking.

R. Fisher, K. Albain, D. Barnes, 1989, Cancer research.

A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma.

R. Fisher, G. Weiss, J. Dutcher, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Kinetic characterization and response to chemotherapy in a transplantable murine ovarian cancer.

R. Fisher, R. Ozols, R. Young, 1979, Cancer research.

Advances in the staging and treatment of ovarian cancer

R. Fisher, R. Young, 1977, Cancer.

Venous thromboembolism in patients with diffuse large B-cell lymphoma

R. Fisher, A. Khorana, C. Francis, 2006, Leukemia & lymphoma.

ŒSTROGEN RECEPTORS IN HUMAN MALIGNANT MELANOMA

R. Fisher, M. Lippman, J. Neifeld, 1976, The Lancet.

Functional heterogeneity of Leu 19"bright"+ and Leu 19"dim"+ lymphokine-activated killer cells.

R. Fisher, T. Ellis, 1989, Journal of immunology.

Ovarian cancer: a solid tumor with evidence of normal cellular immune function but abnormal B cell function.

R. Fisher, R. Young, G. Mandell, 1979, The American journal of medicine.

Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy.

R. Fisher, V. Devita, R. Simon, 1979, The New England journal of medicine.

Lack of histocompatibility antigens on a murine ovarian teratocarcinoma.

R. Fisher, E. Appella, L. Ramanathan, 1981, Cancer research.

Neurotoxicity associated with systemic high-dose cytosine arabinoside.

R. Fisher, S. Fisher, H. Messmore, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Leukemic transformation in polycythemia vera: Analysis of risk factors

R. Fisher, S. Fisher, H. Messmore, 1990, American journal of hematology.

EOE-13 in the detection of hepatosplenic lymphoma.

R. Fisher, M. Bernardino, J. Doppman, 1982, Radiology.

Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study.

L. Rimsza, R. Fisher, R. Braziel, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Interleukin-1-independent activation of human T lymphocytes stimulated by anti-CD3 and a Hodgkin's disease cell line with accessory cell activity.

R. Fisher, U. Gubler, A. O. Chua, 1988, Cellular immunology.

Molecular diagnosis of Burkitt's lymphoma.

Richard Simon, Kai Fu, Jan Delabie, 2006, The New England journal of medicine.

A Randomized Phase III Trial of ABVD Vs. Stanford V +/− Radiation Therapy In Locally Extensive and Advanced Stage Hodgkin's Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperatve Oncology Group (E2496)

R. Advani, R. Gascoyne, L. Gordon, 2010 .

Serum Biomarkers Predict Outcomes in Advanced Hodgkin Lymphoma Independent of International Prognostic Score (IPS) and Treatment: Correlative Analysis from a Large North American Cooperative Group Trial

R. Advani, R. Gascoyne, L. Gordon, 2016 .

A Gene Expression Signature in Diagnostic Formalin Fixed Paraffin Embedded Tissue Predicts Overall Survival in Locally Advanced and Advanced Stage Classical Hodgkin Lymphoma – a Correlative Study From the E2496 Intergroup Trial

R. Gascoyne, D. Scott, L. Gordon, 2011 .

Activity of the Epipodophyllotoxin VP‐16 in the Treatment of Combination Chemotherapy‐Resistant Non‐Hodgkin Lymphoma

R. Fisher, R. Bender, R. Young, 1978, American journal of hematology.

Cancer Therapy : Preclinical Aurora A Inhibitor ( MLN 8237 ) plus Vincristine plus Rituximab Is Synthetic Lethal and a Potential Curative Therapy in Aggressive B-cell Non-Hodgkin Lymphoma

R. Fisher, T. Miller, Ann M Manziello, 2012 .

Deficient helper cell function as a cause of diminished pokeweed mitogen blastogenic responses in patients with non‐Hodgkin's lymphomas

R. Fisher, L. Neckers, F. Bostick-Bruton, 1984, Cancer.

OKT3 monoclonal antibodies induce interleukin-6 and interleukin-10: a possible cause of lymphoproliferative disorders associated with transplantation.

R. Fisher, L. Swinnen, R. I. Fisher, 1993, Current opinion in nephrology and hypertension.

Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen.

R. Fisher, M. Bar, G. Weiss, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis

Sonali M. Smith, J. Friedberg, J. Winter, 2019, Leukemia & lymphoma.

MYC Protein Expression, but Not High Grade Morphology, Is Associated with Poor Outcome in Non-Burkitt Diffuse Aggressive B-Cell Lymphomas: A SWOG S9704 Correlative Study

L. Rimsza, R. Fisher, M. Leblanc, 2012 .

Novel concepts in radioimmunotherapy for non-Hodgkin's lymphoma.

J. Friedberg, R. Fisher, Julia Schaefer-Cutillo, 2007, Oncology.

Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas.

R. Fisher, T. Miller, C. Coltman, 1988, Seminars in hematology.

Hexamethylmelamine in alkylating agent‐resistant ovarian carcinoma

R. Fisher, V. Devita, R. Bender, 1978, Cancer.

A phase I/II study of sequential interleukin-3 and granulocyte-macrophage colony-stimulating factor in myelodysplastic syndromes.

R. Fisher, J. Sosman, S. Nand, 1994, Blood.

Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP ± R for eight cycles to CHOP ± R for six cycles followed by autotransplant for patients with high-intermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgkin lymphoma (NHL).

J. Friedberg, J. Winter, R. Fisher, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multiple recurrences of acute tumor lysis syndrome in an indolent non‐hodgkin's lymphoma

E. Jaffe, R. Fisher, D. Longo, 1985, Cancer.

The biology of tumor growth in the non-Hodgkin's lymphomas. A dual parameter flow cytometry study of 220 cases.

R. Fisher, W. Schuette, R. Simon, 1984, The Journal of clinical investigation.

Reply to M.C. Chamberlain

J. Friedberg, R. Fisher, T. Miller, 2009 .

Diversity of Immunological Phenotypes of Lymphoblastic Lymphoma 1

E. Jaffe, R. Fisher, I. Magrath, 2006 .

MUM1 Expression in Follicular Lymphoma Is a Poor Prognostic Marker in Patients Treated with Immunochemotherapy (SWOG 9800/9911) but Not Chemotherapy Alone (SWOG 8809): A Southwest Oncology Group Correlative Science Study

L. Rimsza, R. Fisher, D. Maloney, 2008 .

Cytotoxic synergy of cisplatin with concurrent hydroxyurea and cytarabine: summary of an in vitro model and initial clinical pilot experience.

R. Fisher, K. Albain, S. Fisher, 1992, Seminars in oncology.

Objective regressions of T- and B-cell lymphomas in patients following treatment with anti-thymocyte globulin.

R. Fisher, J. Cossman, B. Silver, 1982, Cancer research.

A Multi Center Trial of hyperCVAD+Rituxan in Patients with Newly Diagnosed Mantle Cell Lymphoma.

R. Fisher, T. Miller, M. Leblanc, 2007 .

Neoplastic cells obtained from Hodgkin's disease are potent stimulators of human primary mixed lymphocyte cultures.

V. Diehl, R. Fisher, G. Scala, 1983, Journal of immunology.

The PKCβ Selective Inhibitor, Enzastaurin (LY317615), Inhibits Growth of Human Lymphoma Cells.

R. Fisher, A. Henn, C. Jordan, 2005 .

Antigen presentation by Hodgkin's disease cells.

V. Diehl, R. Fisher, J. Cossman, 1985, Journal of immunology.

Controlled clinical trials of nutritional intervention as an adjunct to chemotherapy, with a comment on nutrition and drug resistance.

R. Fisher, M. Brennan, A. Levine, 1982, Cancer research.

Appearance and phenotypic characterization of circulating Leu 19+ cells in cancer patients receiving recombinant interleukin 2.

R. Fisher, J. A. Harris, D. Braun, 1988, Cancer research.

An outbreak of hepatitis A among cancer patients treated with interleukin-2 and lymphokine-activated killer cells.

S. Hadler, R. Fisher, R. Karron, 1990, The Journal of infectious diseases.

Production and characterization of a monoclonal antibody that binds Reed-Sternberg cells.

R. Fisher, D. Longo, M. Israel, 1985, Journal of immunology.

A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma.

R. Fisher, J. Doroshow, G. Weiss, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adverse Events Reported by Patients With Cancer After Administration of a 2-Dose mRNA COVID-19 Vaccine.

R. Fisher, E. Horwitz, R. Uzzo, 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.

J. Connors, R. Fisher, J. Glick, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inguinal and Ilio-inguinal Lymphadenectomy in Management of Palpable Melanoma Lymph Node Metastasis: A Long-Term Prospective Evaluation of Morbidity and Quality of Life

R. Fisher, K. Shannon, R. Scolyer, 2019, Annals of Surgical Oncology.

Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial.

R. Fisher, K. Shannon, R. Scolyer, 2012, The Lancet. Oncology.

Southwest oncology group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas.

R. Fisher, T. Miller, C. Coltman, 1987, Seminars in hematology.

Hypoxia in head and neck cancer: studies with hypoxic positron emission tomography imaging and hypoxic cytotoxins.

R. Fisher, L. Peters, R. Hicks, 2007, International journal of radiation oncology, biology, physics.

Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells In Vitro and In Vivo

Derick R. Peterson, J. Friedberg, R. Fisher, 2012, Molecular Cancer Therapeutics.

Preclinical Development Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Car fi lzomib in GC-and ABC-DLBCL Cells In Vitro and In Vivo

Derick R. Peterson, J. Friedberg, R. Fisher, 2012 .

Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group study.

R. Fisher, T. Miller, H. Eyre, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Increased sensitivity to normal adherent suppressor cells in untreated advanced Hodgkin's disease.

R. Fisher, F. Bostick, C. Vanhaelen, 1981, Blood.

Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas

G. Lenz, R. Fisher, B. Cheson, 2018, Clinical lymphoma, myeloma & leukemia.

A Phase III Multi-Centre Randomised Trial comparing adjuvant versus early salvage Radiotherapy following a Radical Prostatectomy: Results of the TROG 08.03 and ANZUP “RAVES” Trial

R. Fisher, H. Woo, M. Frydenberg, 2019, International Journal of Radiation Oncology*Biology*Physics.

Phase II evaluation of interleukin-4 in patients with non-Hodgkin's lymphoma: a Southwest Oncology Group Trial

R. Fisher, M. Leblanc, D. Moore, 2000, Anti-cancer drugs.

A phase I trial of continuous infusion interleukin-4 (IL-4) alone and following interleukin-2 (IL-2) in cancer patients.

R. Fisher, J. Sosman, S. Fisher, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Implications of persistent T cell abnormalities for the etiology of Hodgkin's disease.

R. Fisher, 1982, Cancer treatment reports.

Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.

E. Jaffe, R. Fisher, P. Duffey, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chromosomal Imbalances in Germinal Center B-Cell-Like and Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Influence Gene Expression Signatures and Improve Gene Expression-Based Survival Prediction(the First Two Authors Contributed Equally to This Work).

L. Staudt, A. Rosenwald, W. Chan, 2004 .

Profound Hypogammaglobulinemia 7 Years after Treatment for Indolent Lymphoma

J. Friedberg, R. Fisher, A. Walker, 2008, Cancer investigation.

A phase II study of PXD101 (belinostat) in relapsed and refractory aggressive B-cell lymphomas (rel/ref ABCL): SWOG S0520.

L. Rimsza, R. Fisher, T. Miller, 2012 .

Predictors of vitality (energy/fatigue) in early stage Hodgkin's disease (HD): Results from Southwest Oncology Group (SWOG) Study 9133.

R. Fisher, D. Pauler, C. Moinpour, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.

R. Fisher, L. Schwartz, B. Cheson, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preclinical Development Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells In Vitro and In Vivo

J. Friedberg, R. Fisher, P. Dent, 2011 .

Autologous bone marrow transplantation using unfractionated cells cryopreserved in dimethylsulfoxide and hydroxyethyl starch without controlled-rate freezing.

R. Fisher, P. Stiff, A. Koester, 1987, Blood.

Dose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small-cell lung carcinoma.

R. Fisher, M. Oken, F. Shepherd, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identification of a Novel CD 56 Lymphokine-activated Killer Cell Precursor in Cancer Patients Receiving Recombinant Interleukin 2 '

R. Fisher, P. Simms, B. Helfrich, 2006 .

Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanoma.

R. Fisher, J. Sosman, J. Doroshow, 1997, Clinical Cancer Research.

Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2.

R. Fisher, P. Simms, B. Helfrich, 1992, Cancer research.

In vivo effects of recombinant IL-2. I. Isolation of circulating Leu-19+ lymphokine-activated killer effector cells from cancer patients receiving recombinant IL-2.

R. Fisher, J. Harris, D. Braun, 1988, Journal of immunology.

l-/3-D-Arabinofuranosylcytosine and Hydroxyurea Production of Cytotoxic Synergy with cis-Diamminedichloroplatinum(II) and Modification of Platinum-induced DNA Interstrand Cross-Linking1

R. Fisher, K. Albain, D. Barnes, 2006 .

A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911.

R. Fisher, T. Miller, M. Leblanc, 2003, Blood.

In reply [11]

R. Fisher, O. Press, 2007 .

Venous Thromboembolic Events in Patients with Diffuse Large B cell Non- Hodgkin’s Lymphoma.

R. Fisher, A. Khorana, C. Francis, 2004 .

A prospective randomized study of adjuvant parenteral nutrition in the treatment of diffuse lymphoma: effect on drug tolerance.

R. Fisher, R. Simon, M. Brennan, 1981, Cancer treatment reports.

SWOG S0410/BMT CTN 0703: A Phase II Trial of Tandem Autologous Stem Cell Transplantation (AHCT) for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma (HL) (ClinicalTrials.gov Identifier: NCT00233987)

J. Friedberg, L. Rimsza, R. Fisher, 2014 .

Advanced insights into the biology of malignant lymphomas.

R. Fisher, 2011, Journal of Clinical Oncology.

A prospective randomized study of adjuvant parenteral nutrition in the treatment of advanced diffuse lymphoma: influence on survival.

R. Fisher, M. Brennan, R. Aamodt, 1981, Surgery.

NCCN guidelines® insights chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017: Featured updates to the NCCN guidelines

J. Byrd, R. Advani, J. Vose, 2017 .

NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017.

J. Byrd, R. Advani, J. Vose, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.

J. Leonard, S. de Vos, R. Fisher, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recommendations for revised response criteria for malignant lymphoma.

V. Diehl, R. Gascoyne, A. Hagenbeek, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014.

L. Rimsza, R. Fisher, T. Miller, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gene Expression Differences between Low and High Stage Diffuse Large B Cell Lymphoma (DLBCL).

L. Staudt, A. Rosenwald, W. Chan, 2006 .

Prospective Study of Sequential Reduction in Immunosuppression, Interferon Alpha-2B, and Chemotherapy for Posttransplantation Lymphoproliferative Disorder

Alan M. Miller, L. Gordon, R. Fisher, 2008, Transplantation.

An outbreak of varicella-zoster virus infection among cancer patients.

R. Fisher, M. Greene, D. Morens, 1980, Annals of internal medicine.

Percutaneous aspiration of retroperitoneal lymph nodes in ovarian cancer.

R. Fisher, N. R. Dunnick, R. Young, 1980, AJR. American journal of roentgenology.

Vorinostat (Suberoylanilide Hydroxamic Acid) in Relapsed or Refractory Hodgkin Lymphoma: SWOG 0517.

L. Rimsza, R. Fisher, S. Forman, 2007 .

Chemotherapy for murine ovarian cancer: a rationale for ip therapy with adriamycin.

R. Fisher, J. Doroshow, R. Ozols, 1979, Cancer treatment reports.

Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma.

R. Fisher, P. Simms, B. Helfrich, 1989, Journal of immunology.

Oncogenically active MYD88 mutations in human lymphoma

Joseph M. Connors, Randy D. Gascoyne, Roland Schmitz, 2011, Nature.

MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial.

R. Fisher, R. Schilsky, M. Oken, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Depressed T cell proliferative responses in Hodgkin's disease: role of monocyte-mediated suppression via prostaglandins and hydrogen peroxide.

R. Fisher, F. Bostick-Bruton, 1982, Journal of immunology.

Association of the human type C retrovirus with a subset of adult T-cell cancers.

W. Blattner, E. Jaffe, R. Fisher, 1983, Cancer research.

Disseminated infection by Fusarium moniliforme during treatment for malignant lymphoma

R. Fisher, K. Kwon-Chung, A. Jennings, 1978, Journal of clinical microbiology.

Disseminated Infection byFusariummoniliforme During Treatment forMalignant Lymphoma

R. Fisher, 1978 .

Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients.

R. Fisher, S. Fisher, L. Swinnen, 1990, The New England journal of medicine.

Head and Neck Squamous Cell Carcinoma

R. Fisher, S. Fox, B. Solomon, 2020, Definitions.

Receptors for steroid hormones in human melanoma.

R. Fisher, M. Lippman, J. Neifeld, 1976, Surgical forum.

Diethylstilbestrol therapy of surgically non-resectable malignant melanoma

R. Fisher, M. Lippman, R. Young, 1978 .

Phase II study of high-dose methotrexate in patients with advanced malignant melanoma.

R. Fisher, B. Chabner, C. Myers, 1979, Cancer treatment reports.

Adjuvant immunotherapy or chemotherapy for malignant melanoma. Preliminary report of the National Cancer Institute randomized clinical trial.

R. Fisher, R. Makuch, S. Rosenberg, 1981, The Surgical clinics of North America.

Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial.

R. Advani, R. Gascoyne, D. Scott, 2012, Blood.

Novel therapeutics for aggressive non-Hodgkin's lymphoma.

R. Fisher, D. Mahadevan, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of streptozocin- and carmustine-sequenced administration in patients with advanced cancer.

R. Fisher, B. Futscher, L. Erickson, 1992, Journal of the National Cancer Institute.

The Role of Bortezomib in the Treatment of Lymphoma

J. Friedberg, R. Fisher, P. Barr, 2007, Cancer investigation.

Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell–like diffuse large B cell lymphoma

L. Staudt, A. Rosenwald, W. Chan, 2007, The Journal of experimental medicine.

Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma.

Sonali M. Smith, R. Fisher, Y. Oki, 2019, Clinical lymphoma, myeloma & leukemia.

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.

R. Fisher, M. Atkins, G. Weiss, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Aberrant Immunoglobulin Class Switch Recombination and Switch Translocations in Activated B Cell-Like Diffuse Large B-Cell Lymphoma.

L. Staudt, A. Rosenwald, W. Chan, 2006 .

Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse.

R. Fisher, V. Devita, R. Simon, 1979, Annals of internal medicine.

The Burkitt-like lymphomas: a Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features.

R. Fisher, T. Grogan, T. Miller, 2001, Blood.

Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group.

V. Diehl, R. Fisher, D. Crowther, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of p16 Status on the Quality-of-Life Experience During Chemoradiation for Locally Advanced Oropharyngeal Cancer: A Substudy of Randomized Trial Trans-Tasman Radiation Oncology Group (TROG) 02.02 (HeadSTART).

R. Fisher, B. O'Sullivan, L. Peters, 2017, International journal of radiation oncology, biology, physics.

Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial.

R. Fisher, H. Woo, M. Frydenberg, 2020, The Lancet Oncology.

Meta-analysis to evaluate the role of interferon in follicular lymphoma.

A. Hagenbeek, T. Lister, R. Fisher, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy.

R. Fisher, D. Longo, V. Devita, 1983, Annals of internal medicine.

Current trends in large cell lymphoma

R. Fisher, P. Shah, 2003, Leukemia.

Current therapeutic paradigm for the treatment of non-Hodgkin's lymphoma.

R. Fisher, 2000, Seminars in oncology.

Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project.

L. Staudt, A. Rosenwald, W. Chan, 2004, Blood.

Factors predicting long-term survival in diffuse mixed, histiocytic, or undifferentiated lymphoma.

R. Fisher, V. Devita, J. Cossman, 1981, Blood.

Diffuse large B-cell lymphoma.

J. Friedberg, R. Fisher, 2008, Hematology/oncology clinics of North America.

Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease.

R. Fisher, T. Grogan, T. Miller, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Southwest Oncology Group perspective on the Revised European-American Lymphoma classification.

R. Fisher, T. Grogan, T. Miller, 1997, Hematology/oncology clinics of North America.

Aggressive treatment for postcardiac transplant lymphoproliferation.

R. Fisher, L. Swinnen, M. Costanzo, 1995, Blood.

A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study.

B. Nathwani, R. Fisher, T. Grogan, 1995, Blood.

Prolonged initial remission in patients with nodular mixed lymphoma.

E. Jaffe, R. Fisher, D. Longo, 1984, Annals of internal medicine.

Combination chemotherapy in non-Hodgkin's lymphoma: results of long-term followup.

R. Fisher, L. Norton, V. Devita, 1977, Cancer treatment reports.

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.

R. Fisher, S. Rosenberg, M. Sznol, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496).

R. Advani, R. Gascoyne, L. Gordon, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis.

J. Friedberg, R. Fisher, P. Dent, 2010, Leukemia research.

Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy.

R. Fisher, R. Wittes, P. Duffey, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy.

R. Fisher, V. Devita, R. Simon, 1978, The New England journal of medicine.

RB but not R‐HCVAD is a feasible induction regimen prior to auto‐HCT in frontline MCL: results of SWOG Study S1106

Sonali M. Smith, J. Friedberg, J. Leonard, 2017, British journal of haematology.

US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.

R. Gascoyne, A. LaCasce, J. Friedberg, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496

R. Advani, R. Gascoyne, L. Gordon, 2013, British journal of haematology.

A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108

L. Rimsza, R. Fisher, T. Miller, 2009, Leukemia & lymphoma.

Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumors.

R. Fisher, M. Atkins, G. Weiss, 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Immunologic phenotypes of diffuse, aggressive, non‐Hodgkin's lymphomas. Correlation with clinical features

E. Jaffe, R. Fisher, J. Cossman, 1984, Cancer.

The epidemiology of non-Hodgkin's lymphoma

R. Fisher, S. Fisher, 2004, Oncogene.

Lymphoma classification--the gap between biology and clinical management is closing.

W Hiddemann, J. Armitage, F. Cavalli, 1996, Blood.

The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial.

A. Nademanee, R. Fisher, M. Leblanc, 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Randomized C omparison o f A BVD a nd M OPP/ABV H ybrid f or the T reatment o f A dvanced H odgkin's D isease: R eport o f a n Intergroup T rial

J. Connors, R. Fisher, J. Glick, 2003 .

Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy.

B. Nathwani, R. Fisher, T. Miller, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group.

J. Friedberg, R. Fisher, T. Miller, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized trial comparing fluorocholine-PET/CT with conventional imaging in prostate cancer.

R. Fisher, R. Hicks, P. Roselt, 2019, Journal of Clinical Oncology.

Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016.

Sonali M. Smith, M. Kaminski, J. Friedberg, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + 131Iodine—Tositumomab

M. Kaminski, M. Czuczman, J. Friedberg, 2013, Clinical Cancer Research.

Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016.

M. Kaminski, M. Czuczman, J. Friedberg, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Overview of non-Hodgkin's lymphoma: biology, staging, and treatment.

R. Fisher, 2003, Seminars in oncology.

Diffuse large-cell lymphomas: a review of therapy.

R. Fisher, J E Godwin, R I Fisher, 2001, Clinical lymphoma.

Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.

J. Vose, M. Czuczman, R. Fisher, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Diffuse large-cell lymphoma.

R. Fisher, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I/II trial of vorinostat (SAHA) in combination with rituximab‐CHOP in patients with newly diagnosed advanced stage diffuse large B‐cell lymphoma (DLBCL): SWOG S0806

Sonali M. Smith, J. Friedberg, L. Rimsza, 2015, American journal of hematology.

A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520

Sonali M. Smith, J. Friedberg, L. Rimsza, 2016, Leukemia & lymphoma.

The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin's lymphoma: an evidence-based review.

J. Vose, M. Czuczman, R. Fisher, 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas

J. Friedberg, R. Fisher, D. Neuberg, 2009, British journal of haematology.

Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma.

R. Fisher, T. Grogan, T. Miller, 1998, The New England journal of medicine.

Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens--a Southwest Oncology Group trial.

R. Fisher, S. Horning, S. Forman, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Follicular lymphomas: do histologic subtypes predict outcome?

R. Fisher, T. Grogan, T. Miller, 1997, Hematology/oncology clinics of North America.

Activity of esorubicin in recurrent malignant lymphoma: a Southwest Oncology Group study.

R. Fisher, T. Miller, S. Salmon, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combination chemotherapy of intermediate-grade and high-grade non-Hodgkin's lymphoma with MACOP-B: a Southwest Oncology Group study.

R. Fisher, T. Miller, S. Balcerzak, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FDG-PET-Detected Extracranial Metastasis in Patients with Non-Small Cell Lung Cancer Undergoing Staging for Surgery or Radical Radiotherapy

R. Fisher, D. Ball, R. Hicks, 2003, Acta oncologica.

Regression of a T-cell lymphoma after administration of antithymocyte globulin.

R. Fisher, S. Broder, R. Young, 1978, Annals of internal medicine.

Clinical trials with a new intravenous liposoluble contrast material for computed tomography of the liver and spleen.

R. Fisher, J. Doppman, R. Adamson, 1980, Radiology.

survival in mantle cell lymphoma mRNAs that are associated with increased proliferation rate and shorter Point mutations and genomic deletions in Cyclin D1 create stable truncated

L. Staudt, A. Rosenwald, W. Chan, 2013 .

Point mutations and genomic deletions in Cyclin D1 create stable truncated mRNAs that are associated with increased proliferation rate and shorter survival in mantle cell lymphoma Lymphoma/Leukemia Molecular Profiling

L. Staudt, A. Rosenwald, W. Chan, 2007 .

Nephrotoxicity of semustine (methyl-CCNU) in patients with malignant melanoma receiving adjuvant chemotherapy.

R. Fisher, K. Micetich, J. Mandard, 1981, The American journal of medicine.

Prognostic and Predictive Significance of Plasma HGF and IL-8 in a Phase III Trial of Chemoradiation with or without Tirapazamine in Locoregionally Advanced Head and Neck Cancer

R. Fisher, B. O'Sullivan, A. Giaccia, 2012, Clinical Cancer Research.

Prognostic and Predictive Significance of Plasma HGF and IL-8 in a Phase III Trial of Chemoradiation with or without Tirapazamine in Locoregionally Advanced Head and Neck Cancer

R. Fisher, B. O'Sullivan, A. Giaccia, 2012, Clinical Cancer Research.

A phase I/II study of sequential interleukin-3 and granulocyte- macrophage colony-stimulating factor in myelodysplastic syndromes

R. Fisher, J. Sosman, S. Nand, 1994 .

Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy.

R. Fisher, V. Devita, R. Simon, 1977, The American journal of medicine.

BCL-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress

J. Friedberg, R. Fisher, P. Dent, 2009, Cancer biology & therapy.

Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions.

L. Staudt, A. Rosenwald, W. Chan, 2005, Blood.

Chapter 4 Molecular Diagnosis of Burkitt lymphoma

Armitage, L. Staudt, A. Rosenwald, 2019 .

A War on Two Fronts: Cancer Care in the Time of COVID-19

R. Fisher, M. Edelman, E. Horwitz, 2020, Annals of Internal Medicine.

Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001.

Sonali M. Smith, J. Friedberg, J. Leonard, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma.

R. Fisher, S. Rosenberg, G. Fyfe, 2000, The cancer journal from Scientific American.

Diffuse aggressive lymphoma.

R. Fisher, T. Miller, O. O’Connor, 2004, Hematology. American Society of Hematology. Education Program.

Diffuse large B-cell NHL.

J. Friedberg, R. Fisher, 2006, Cancer treatment and research.

Rituximab-CHOP Versus CHOP with or without Maintenance Rituximab in Patients 60 Years of Age or Older with Diffuse Large B-Cell Lymphoma (DLBCL): An Update.

R. Gascoyne, R. Fisher, T. Habermann, 2004 .

New treatment options have changed the survival of patients with follicular lymphoma.

R. Fisher, T. Miller, M. Leblanc, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The staging and treatment of epithelial ovarian cancer.

R. Fisher, R. Young, 1978, Canadian Medical Association journal.

Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study.

R. Gascoyne, J. Winter, R. Fisher, 2006, Blood.

Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial.

J. Vose, R. Fisher, M. Horowitz, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study.

R. Fisher, M. Atkins, J. Sosman, 1997, The cancer journal from Scientific American.

International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)

W. Wilson, V. Seshan, R. Advani, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Is observation dead in follicular lymphoma? No, but the apoptosis pathway has been activated.

R. Fisher, Richard I Fisher, Nadia Khan, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B‐cell lymphoma treated with R‐CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E‐IPI)

R. Advani, R. Gascoyne, R. Fisher, 2010, British journal of haematology.

Randomised trial of radiotherapy with weekly cisplatin or cetuximab in low risk HPV associated oropharyngeal cancer (TROG 12.01) - a Trans-Tasman Radiation Oncology Group study.

R. Fisher, D. Rischin, Lachlan McDowell, 2021, International journal of radiation oncology, biology, physics.

Phase III study of tirapazamine, cisplatin and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck

R. Fisher, J. Bourhis, B. O'Sullivan, 2008 .

Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02).

R. Fisher, L. Peters, D. Rischin, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells In Vitro and In Vivo

J. Friedberg, R. Fisher, P. Dent, 2011, Molecular Cancer Therapeutics.

Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.

Sonali M. Smith, J. Friedberg, C. Flowers, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas.

J. Vose, A. Zelenetz, M. Kaminski, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma.

J. Friedberg, R. Fisher, J. Liesveld, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Outcome of patients > age 40 with Burkitt lymphoma (BL) treated with aggressive chemotherapuetic regimens : Results from the international Burkitt lymphoma collaborative group

A. LaCasce, J. Friedberg, R. Fisher, 2005 .

R‐CHOP with iodine‐131 tositumomab consolidation for advanced stage diffuse large B‐cell lymphoma (DLBCL): SWOG S0433

A. Nademanee, M. Kaminski, J. Friedberg, 2014, British journal of haematology.

Immunohistochemi-NCCN Diffuse Large B-Cell Lymphoma Version 1 . 2016 Clinical Practice Guidelines in Oncology

J. Byrd, R. Advani, J. Vose, 2016 .

Report o f a n I nternational W orkshop t o S tandardize Response C riteria f or N on-Hodgkin's L ymphomas

J. Armitage, J. Vose, A. Hagenbeek, 1999 .

Amonafide treatment of refractory esophageal cancer

R. Fisher, J. Macdonald, E. Poplin, 1993, Investigational New Drugs.

A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213.

L. Rimsza, R. Fisher, T. Miller, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.

L. Staudt, W. Wilson, A. Zelenetz, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Alteration of SMRT tumor suppressor function in transformed non-Hodgkin lymphomas.

R. Fisher, T. Grogan, D. Catovsky, 2005, Cancer research.

Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy.

R. Fisher, S. Rosenberg, M. Sznol, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Origin and biologic function of Reed-Sternberg cells

V. Diehl, R. Fisher, D. Longo, 1985 .

Adjuvant radiotherapy and regional lymph node field control in melanoma patients after lymphadenectomy: Results of an intergroup randomized trial (ANZMTG 01.02/TROG 02.01).

R. Fisher, K. Shannon, R. Scolyer, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase II Clinical Trial of Interleukin‐2 and Lymphokine‐Activated Killer Cells in Advanced Colorectal Carcinoma

R. Fisher, M. Atkins, J. Doroshow, 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Clinical trials of alpha-interferon in the treatment of non-Hodgkin's lymphoma.

R. Fisher, E. Gaynor, 1991, Seminars in Oncology.

The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells.

R. Fisher, S. Fisher, S. Creekmore, 1988, Annals of internal medicine.

High-Dose R ecombinant I nterleukin 2 T herapy f or P atients With M etastatic M elanoma: A nalysis o f 2 70 P atients Treated B etween 1 985 a nd 1 993

R. Fisher, M. Atkins, G. Weiss, 1999 .

Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma.

R. Fisher, J. Doroshow, G. Weiss, 1989, Journal of the National Cancer Institute.

Non-Hodgkin's lymphomas after treatment of Hodgkin's disease.

R. Fisher, 1983, Archives of internal medicine.

Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997.

R. Fisher, J. Sosman, G. Weiss, 1997, The cancer journal from Scientific American.

Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma.

R. Fisher, M. Atkins, J. Doroshow, 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone

L. Rimsza, R. Fisher, T. Miller, 2012, Haematologica.

A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high‐risk features: background and rationale of the Radiotherapy – Adjuvant Versus Early Salvage (RAVES) trial

R. Fisher, H. Woo, M. Frydenberg, 2014, BJU international.

Use of Intravenous Liposoluble Contrast Material for the Examination of the Liver and Spleen in Lymphoma

R. Fisher, M. Bernardino, J. Doppman, 1981, Journal of computer assisted tomography.

diffuse, aggressive non-Hodgkin's lymphomas Prognostic implications of ploidy and proliferative activity in the

L. Gordon, J. Winter, R. Fisher, 2011 .

Prognostic implications of ploidy and proliferative activity in the diffuse, aggressive non-Hodgkin's lymphomas.

L. Gordon, J. Winter, R. Fisher, 1996, Blood.

Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma.

Derick R. Peterson, J. Friedberg, L. Rimsza, 2014, Blood.

Natural history of malignant lymphomas with divergent histologies at staging evaluation

R. Fisher, V. Devita, R. Simon, 1981, Cancer.

Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study.

J. Friedberg, R. Fisher, G. Lyman, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.

R. Fisher, T. Miller, M. Leblanc, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of R‐CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601

Sonali M. Smith, J. Friedberg, L. Rimsza, 2016, British journal of haematology.

Radiation consolidation following MOP-BAP for stages III & IV Hodgkin's disease, A randomized Southwest Oncology study

R. Fisher, T. Miller, C. Coltman, 1991 .

Genetic polymorphisms in oxidative stress‐related genes are associated with outcomes following treatment for aggressive B‐cell non‐Hodgkin lymphoma

J. Cerhan, L. Rimsza, R. Fisher, 2014, American journal of hematology.

Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era.

J. Vose, M. Bast, R. Fisher, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Maintenance rituximab (MR) compared to observation (OBS) after R-CHOP or CHOP in older patients (pts) with diffuse large B-cell lymphoma (DLBCL): An Intergroup E4494/C9793 update

R. Gascoyne, R. Fisher, T. Habermann, 2007 .

Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the Intergroup experience (CALGB 9793; ECOG-SWOG 4494)

R. Fisher, B. Cheson, T. Habermann, 2017, Leukemia & lymphoma.

Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomized trial by the Southwest Oncology Group (SWO

A. Nademanee, R. Fisher, M. Leblanc, 2006, Blood.

Continued Excellent Outcomes in Previously Untreated Follicular Lymphoma Patients after Treatment with CHOP Plus Rituximab or CHOP Plus (131) Iodine-Tositumomab - Long Term Follow-up of Phase III Randomized Study SWOG S0016

Sonali M. Smith, M. Kaminski, J. Friedberg, 2016 .

Diffuse Large B-Cell Lymphoma Version 1.2016.

J. Byrd, R. Advani, J. Vose, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Clinical practice guidelines: non-Hodgkin's lymphomas.

R. Fisher, M. Oken, 1995, Cleveland Clinic journal of medicine.

The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large cell B-cell non-Hodgkin's lymphoma.

J. Vose, M. Czuczman, R. Fisher, 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Characterization of the lymphocyte surface receptors for Con A and PHA.

R. Fisher, P. Henkart, P. Henkart, 1975, Journal of immunology.

Biochemical and structural properties of a Hodgkin's disease-related membrane protein.

R. Fisher, J. Nawrocki, E. Kirsten, 1988, Journal of immunology.

Clinical Significance of MYC Expression and/or “High-grade” Morphology in Non-Burkitt, Diffuse Aggressive B-cell Lymphomas: A SWOG S9704 Correlative Study

L. Rimsza, R. Fisher, M. Leblanc, 2014, The American journal of surgical pathology.

Natural history of malignant melanoma as related to therapy.

R. Fisher, V. Devita, 1976, Cancer treatment reports.

Diffuse large B-cell lymphoma.

J. Friedberg, R. Fisher, 2008, Hematology/oncology clinics of North America.

Expression of p21 Protein Predicts Clinical Outcome in DLBCL Patients Older than 60 Years Treated with R-CHOP but not CHOP: A Prospective ECOG and Southwest Oncology Group Correlative Study on E4494

R. Gascoyne, J. Winter, R. Fisher, 2010, Clinical Cancer Research.

Expression of p 21 Protein Predicts Clinical Outcome in DLBCL Patients Older than 60 Years Treated with R-CHOP but not CHOP : A Prospective ECOG and Southwest Oncology Group Correlative Study on E 4494

R. Gascoyne, J. Winter, R. Fisher, 2010 .

11 – Preclinical and Clinical Experiences with Drug Combinations Designed to Inhibit DNA Repair in Resistant Human Tumor Cells

R. Fisher, L. Erickson, K. Micetich, 1988 .

Gene Expression Signatures Predict Overall Survial in Diffuse Large B Cell Lymphoma Treated with Rituximab and Chop-Like Chemotherapy.

L. Staudt, A. Rosenwald, J. Powell, 2007 .

Subtype-specific therapy for DLBCL: are we there yet?

R. Fisher, N. Khan, 2015, Blood.

Phase II Trial of Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab (R-CHOP) Plus Bevacizumab for Advanced Stage Diffuse Large B-Cell (DLBCL) NHL: Southwest Oncology Group Study S0515

L. Rimsza, R. Fisher, T. Miller, 2010 .

Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809.

R. Fisher, T. Miller, J. Forman, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial

G. Mulligan, R. Fisher, M. Fleming, 2010, Leukemia & lymphoma.

The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo.

J. Friedberg, R. Fisher, P. Dent, 2010, Blood.

Prognostic significance of p53/p21 expression in DLBCL treated with CHOP or R-CHOP: A correlative study of E4494

R. Gascoyne, J. Winter, R. Fisher, 2007 .

Gene expression distinguishes Burkitt lymphoma from other aggressive lymphomas and identifies patients who are highly curable with intensive chemotherapeutic regimens.

L. Staudt, A. Rosenwald, J. Powell, 2005 .

Measurement of lung tumor volumes using three-dimensional computer planning software.

R. Fisher, P. Bowden, M. Millward, 2002, International journal of radiation oncology, biology, physics.

Evaluation of the International Prognostic Score (IPS‐7) and a Simpler Prognostic Score (IPS‐3) for advanced Hodgkin lymphoma in the modern era

R. Advani, R. Gascoyne, L. Gordon, 2015, British journal of haematology.

Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial.

R. Advani, R. Gascoyne, L. Gordon, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313.

J. Friedberg, R. Fisher, T. Miller, 2015, Blood.

Alisertib Added to Rituximab and Vincristine Is Synthetic Lethal and Potentially Curative in Mice with Aggressive DLBCL Co-Overexpressing MYC and BCL2

D. Mount, R. Fisher, T. Miller, 2014, PloS one.

Overview of Southwest Oncology Group clinical trials in non-Hodgkin lymphoma.

R. Fisher, 2005, Clinical advances in hematology & oncology : H&O.

Effect of Adding Rituximab to Three Cycles of CHOP Plus Invoved-Field Radiotherapy for Limited-Stage Aggressive Diffuse B-Cell Lymphoma (SWOG-0014).

R. Fisher, T. Miller, M. Leblanc, 2004 .

CpG Oligonucleotide (1018 ISS) May Overcome Rituximab (R) Resistance in Follicular Lymphoma (FL) through Enhanced ADCC, T Cell Expansion, and Alteration of Tumor Microenvironment.

J. Friedberg, R. Fisher, R. Coffman, 2005 .

Thromboembolism in hospitalized neutropenic cancer patients.

R. Fisher, A. Khorana, C. Francis, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase III Randomized Intergroup Trial (SWOG S0016) of CHOP Chemotherapy Plus Rituximab Vs. CHOP Chemotherapy Plus Iodine-131-Tositumomab for the Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphoma

M. Kaminski, M. Czuczman, J. Friedberg, 2011 .

A comparison of quality of life in patients with T3 rectal cancer receiving short course versus long course preoperative radiation. A Trans-Tasman Radiation Oncology Group Trial (TROG 01.04)

R. Fisher, B. Burmeister, M. Solomon, 2008 .

'Boomerang' technique: an improved method for conformal treatment of locally advanced nasopharyngeal cancer.

R. Fisher, L. Peters, D. Rischin, 2004, Australasian radiology.

Mantle cell lymphoma: at last, some hope for successful innovative treatment strategies.

R. Fisher, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of nodal primary versus extranodal primary histiocytic lymphoma.

R. Fisher, K. Hande, R. Reimer, 1977, Cancer treatment reports.

Retraction: Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells In Vitro and In Vivo

J. Friedberg, R. Fisher, P. Dent, 2019, Molecular Cancer Therapeutics.

Neoplastic cells obtained from Hodgkin's disease function as accessory cells for mitogen-induced human T cell proliferative responses.

V. Diehl, R. Fisher, S. Bates, 1984, Journal of immunology.

Phase II trial of recombinant human interferon alpha in myelodysplastic syndromes.

R. Fisher, S. Fisher, H. Messmore, 1992, Leukemia.

Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma.

R. Advani, R. Gascoyne, D. Scott, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515.

L. Rimsza, R. Fisher, T. Miller, 2012, Blood.

Expression of VEGF, VEGF Receptors, and Other Angiogenic Markers in Relapsed Aggressive Non-Hodgkin’s Lymphoma : Correlative Sudies from the SWOG S0108 Trial.

L. Rimsza, R. Fisher, A. Stopeck, 2004 .

New Treatment Options Have Changed the Natural History of Follicular Lymphoma.

R. Fisher, T. Miller, M. Leblanc, 2004 .

University of Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics

Waldmann, Meili, L. Staudt, 2012 .

Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin’s disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208

M. Kaminski, R. Fisher, C. Moinpour, 2017, Journal of Cancer Survivorship.

Health status and quality of life in patients with early-stage Hodgkin's disease treated on Southwest Oncology Group Study 9133.

R. Fisher, D. Pauler, C. Moinpour, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Health S tatus a nd Q uality o f L ife i n P atients W ith Early-Stage H odgkin's D isease T reated o n S outhwest O ncology Group S tudy 9 133

R. Fisher, D. Pauler, C. Moinpour, 2003 .

Clinicopathologic Correlates of the REAL Classification

Richard I. Fisher, R. Fisher, 1998 .

Effect of Adding Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy Consolidation to Three Cycles of CHOP Plus Involved-Field Radiotherapy for Limited-Stage Aggressive Diffuse B-Cell Lymphoma (SWOG 0313)

J. Friedberg, R. Fisher, T. Miller, 2008 .

Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent

Lester J. Peters, Rodney J. Hicks, Richard Fisher, 2005, European Journal of Nuclear Medicine and Molecular Imaging.

Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in Hodgkin's disease and non-Hodgkin's lymphoma.

R. Fisher, M. Atkins, J. Doroshow, 1991, Journal of immunotherapy : official journal of the Society for Biological Therapy.

Early Diagnosis, Treatment and Care of Cancer Patients

R. Fisher, 2008 .

Immunology and cellular biology of Hodgkin's disease.

R. Fisher, J. Nawrocki, D. Slivnick, 1989, Hematology/oncology clinics of North America.

Bortezomib in relapsed or refractory mantle cell lymphoma (MCL): Results of the PINNACLE study.

R. Fisher, B. Djulbegovic, A. Boral, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lymphdx: A Custom Microarray for Molecular Diagnosis and Prognosis in Non-Hodgkin Lymphoma.

L. Staudt, A. Rosenwald, J. Powell, 2004 .

Efficacy and tolerability of ABVD and Stanford V for elderly advanced-stage Hodgkin lymphoma (HL): Analysis from the phase III randomized U.S. Intergroup Trial E2496.

R. Advani, L. Gordon, J. Connors, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Irreversible Proteasome Inhibitor Carfilzomib Interacts Synergistically with the Selective HDAC6 Inhibitor ACY1215 in ABC- and GC-DLBCL and Mantle Cell Lymphoma Sensitive or Resistant to Bortezomib.

J. Friedberg, R. Fisher, S. Grant, 2012 .

Fc Gamma Receptor 3a Genotype Predicts Overall Survival for Follicular Lymphoma Patients Treated On Southwest Oncology Group Trials with Combined Monoclonal Antibody Plus Chemotherapy but Not Chemotherapy Alone.

L. Rimsza, R. Fisher, T. Miller, 2009 .

Patterns of Failure in Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma (HL) Treated with ABVD + Radiotherapy or the Stanford V Regimen in the Randomized Phase III North American Intergroup Trial: E2496

R. Advani, R. Gascoyne, L. Gordon, 2011 .

Phase III Randomized Study of R-CHOP Versus DA-EPOCH-R and Molecular Analysis of Untreated Diffuse Large B-Cell Lymphoma: CALGB/Alliance 50303

Scott E. Smith, L. Staudt, W. Wilson, 2016 .

Adjuvant Radiotherapy Improves Regional (Lymph Node Field) Control in Melanoma Patients after Lymphadenectomy

R. Fisher, H. Hoekstra, A. Hong, 2009 .

R-CHOP with Iodine-131 Tositumomab Consolidation for Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): Southwest Oncology Group Protocol S0433

J. Friedberg, R. Fisher, T. Miller, 2010 .

Clinical verification of the superiority of the current International Union Against Cancer staging criteria in an Australian population of patients with nasopharyngeal carcinoma.

R. Fisher, L. Peters, R. Fisher, 2004, Australasian radiology.

A Phase IA/IB Trial of Anti‐CD3 Murine Monoclonal Antibody plus Low‐Dose Continuous‐Infusion Interleukin‐2 in Advanced Cancer Patients

R. Fisher, J. Sosman, T. Ellis, 1995, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease.

J. Armitage, V. Diehl, T. Lister, 1998, The New England journal of medicine.

R-CHOP Versus (vs) CHOP Followed by Maintenance Rituximab (MR) Vs Observation In Older Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Long-Term Follow-up of Intergroup E4494/C9793

R. Fisher, B. Cheson, T. Habermann, 2010 .

Combined modality treatment using concurrent radiotherapy and pharmacologically-guided carboplatin for inoperable and incompletely resected non-small cell lung cancer.

R. Fisher, M. Millward, D. Ball, 2001, Lung cancer.

Chemotherapy of ovarian cancer.

R. Fisher, R. Ozols, R. Young, 1978, The Surgical clinics of North America.

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.

Meland, L. Staudt, A. Rosenwald, 2002, The New England journal of medicine.

Clinical Trials and Observations

A. Nademanee, R. Fisher, J. Unger, 2008 .